HHS OIG Report Cites Problems With FDA Oversight Of Clinical Trials

Main Category: Clinical Trials / Drug Trials
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 01 Oct 2007 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:2 stars

2 (1 votes)


FDA does not take adequate action to ensure the safety of millions of participants in clinical trials, according to a report from the HHS Office of Inspector General scheduled for release on Friday, the New York Times reports.

According to the report, written by HHS Inspector General Daniel Levinson, FDA -- which oversees trials conducted by companies that seek approval to market medications and medical devices -- lacks information on the number of ongoing trials, audits less than 1% of trial sites and often performs inspections of the sites after the completion of trials. FDA has 200 inspectors, some of whom audit trials part time, to inspect about 350,000 sites, the report found. In addition, the report found that FDA officials downgrade serious violations found by inspectors at trial sites 68% of the time and that the agency in many cases does not perform additional inspections to determine whether recommended corrective actions occurred.

The report recommended that FDA establish a registry of all ongoing trials, a complete registry of research ethics boards and a database of inspections of trial sites, as well as obtain more authority to regulate research assistants.

According to some research ethics experts, the problems with FDA oversight of trials cited in the report are, "in many ways, identical to criticisms leveled at other agency functions, including its oversight of imported food, foreign drug manufacturers, animal food and the safety of older medicines," as the "size and complexity of the tasks facing the agency have grown enormously as the number of inspectors for those tasks has generally declined," the Times reports (Harris, New York Times, 9/28).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Article adapted by Medical News Today from original press release.
Visit our clinical trials / drug trials section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "HHS OIG Report Cites Problems With FDA Oversight Of Clinical Trials." Medical News Today. MediLexicon, Intl., 1 Oct. 2007. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/84094.php>

APA
Kaiser. (2007, October 1). "HHS OIG Report Cites Problems With FDA Oversight Of Clinical Trials." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/84094.php.

Please note: If no author information is provided, the source is cited instead.


Clinical Trials / Drug Trials

Most Popular Articles



Follow Our Clinical Trials News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Clinical Trials / Drug Trials Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »